Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This is an open label phase 1/1b study of Rilotumumab in Japanese subjects with advanced
solid tumors or metastatic gastric esphagogastric (GEJ) adenocarcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal Immunoglobulin G Rilotumumab